Company Profile For Cougar Biotechnology, Inc.

Cougar Biotechnology, Inc. is a development-stage biopharmaceutical company that acquires and develops products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use. As of December 31, 2008, it had rights to three clinical-stage drug candidates: CB7630 (abiraterone acetate), which the Company is developing for the treatment of advanced prostate cancer and breast cancer; CB3304 (noscapine and related analogs), which it is developing for the treatment of hematological malignancies (non-Hodgkin’s lymphoma and multiple myeloma), and CB1089 (seocalcitol), an analog of vitamin D, which the Company is developing for the treatment of cancer. In July 2009, Johnson & Johnson completed the acquisition of Cougar Biotechnology with approximately 95.9% interest in Cougar Biotechnology's outstanding common stock.

BRIEF: For the three months ended 31 March 2009, Cougar Biotechnology, Inc. reported no revenues. Net loss applic. to Common totaled $23.3M, up from $6.4M. Revenues reflect that the Company is still being in the development stages of its operations. Net loss reflects an increase in the research & development expense, higher depreciation charges, a rise in the general & administrative expenses and a decrease in the interest income.

Cougar Biotechnology, Inc.
10990 Wilshire Blvd
Suite 1200
Los Angeles   CA   90024
P: +1310.9438040
F: +1310.9438059

54